Reducing reliance on corticosteroids with rituximab: renewed hope for adult-onset patients with relapsing nephrotic syndrome
Osaka, Japan – One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. However, what about patients who developed nephrotic syndrome in adulthood? As this drug is not yet approved for use in adult-onset patients, researchers from Japan wanted to highlight the profound benefits that rituximab has in adult-onset patients with these challenging conditions.
Nephrotic syndrome is a kidney disorder that causes the body to excrete too much protein in the urine. This condition can lead to edema, weight gain, and an increased risk of infections. ...